<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font3" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font6" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font7" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="6" family="AkzidenzGroteskBE" color="#000000"/>
<text top="42" left="56" width="181" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Breast Cancer Research Vol 8 No 6    Harris et al.<b>Breast Cancer Research</b></text>
<text top="758" left="56" width="49" height="7" font="font1" id="p1_t2" reading_order_no="102" segment_no="13" tag_type="text">Page 10 of 12</text>
<text top="768" left="56" width="120" height="6" font="font3" id="p1_t3" reading_order_no="103" segment_no="14" tag_type="text">(page number not for citation purposes)<i>et al.</i></text>
<text top="226" left="56" width="240" height="9" font="font4" id="p1_t4" reading_order_no="21" segment_no="5" tag_type="text">result of hormone receptor status need to be considered in</text>
<text top="238" left="56" width="241" height="9" font="font4" id="p1_t5" reading_order_no="22" segment_no="5" tag_type="text">analyses of trials in the metastatic setting, even among patient<i>(page number not for citation purposes)</i></text>
<text top="250" left="56" width="234" height="9" font="font4" id="p1_t6" reading_order_no="23" segment_no="5" tag_type="text">populations that have previously received hormonal therapy.</text>
<text top="273" left="56" width="240" height="9" font="font4" id="p1_t7" reading_order_no="24" segment_no="7" tag_type="text">We further evaluated the relationship among p53 status, race,</text>
<text top="285" left="56" width="240" height="9" font="font4" id="p1_t8" reading_order_no="25" segment_no="7" tag_type="text">and outcomes in this cohort. We found that the presence of</text>
<text top="297" left="56" width="241" height="9" font="font4" id="p1_t9" reading_order_no="26" segment_no="7" tag_type="text">p53 over-expression, as detected by IHC, was not predictive</text>
<text top="308" left="56" width="240" height="9" font="font4" id="p1_t10" reading_order_no="27" segment_no="7" tag_type="text">of the response to paclitaxel but was associated with signifi-</text>
<text top="320" left="56" width="240" height="9" font="font4" id="p1_t11" reading_order_no="28" segment_no="7" tag_type="text">cantly diminished OS. There are two possible explanations for</text>
<text top="332" left="56" width="241" height="9" font="font4" id="p1_t12" reading_order_no="29" segment_no="7" tag_type="text">these findings. First, mutations in p53 may lead to genomic</text>
<text top="344" left="56" width="241" height="9" font="font4" id="p1_t13" reading_order_no="30" segment_no="7" tag_type="text">instability in vitro , with resistant clones arising more rapidly in</text>
<text top="355" left="56" width="240" height="9" font="font4" id="p1_t14" reading_order_no="31" segment_no="7" tag_type="text">these tumors, even though the initial response to therapy is the</text>
<text top="367" left="56" width="240" height="9" font="font4" id="p1_t15" reading_order_no="32" segment_no="7" tag_type="text">same as that in tumors without p53 mutations. It is also possi-</text>
<text top="379" left="56" width="240" height="9" font="font4" id="p1_t16" reading_order_no="33" segment_no="7" tag_type="text">ble that other tumor features that predict a worse prognosis<i>in vitro</i></text>
<text top="391" left="56" width="240" height="9" font="font4" id="p1_t17" reading_order_no="34" segment_no="7" tag_type="text">are associated with p53 mutations and influence survival with-</text>
<text top="402" left="56" width="132" height="9" font="font4" id="p1_t18" reading_order_no="35" segment_no="7" tag_type="text">out affecting response to therapy.</text>
<text top="426" left="56" width="240" height="9" font="font4" id="p1_t19" reading_order_no="36" segment_no="8" tag_type="text">In this study p53 over-expression, as determined by IHC, was</text>
<text top="438" left="56" width="241" height="9" font="font4" id="p1_t20" reading_order_no="37" segment_no="8" tag_type="text">associated with decreased survival, but p53 mutations identi-</text>
<text top="449" left="56" width="240" height="9" font="font4" id="p1_t21" reading_order_no="38" segment_no="8" tag_type="text">fied by sequence analysis were not. Explanations include the</text>
<text top="461" left="56" width="240" height="9" font="font4" id="p1_t22" reading_order_no="39" segment_no="8" tag_type="text">possibility that certain p53 mutations have little effect on the</text>
<text top="473" left="56" width="240" height="9" font="font4" id="p1_t23" reading_order_no="40" segment_no="8" tag_type="text">tumor phenotype, whereas the presence of p53 stabilization is</text>
<text top="485" left="56" width="241" height="9" font="font4" id="p1_t24" reading_order_no="41" segment_no="8" tag_type="text">a surrogate for a mutation with a functional effect. The study</text>
<text top="496" left="56" width="240" height="9" font="font4" id="p1_t25" reading_order_no="42" segment_no="8" tag_type="text">was not sufficiently powered to allow for a rigorous examina-</text>
<text top="508" left="56" width="241" height="9" font="font4" id="p1_t26" reading_order_no="43" segment_no="8" tag_type="text">tion of the interaction between mutation type and clinical out-</text>
<text top="520" left="56" width="241" height="9" font="font4" id="p1_t27" reading_order_no="44" segment_no="8" tag_type="text">come. Furthermore, previously described p53 mutations were</text>
<text top="532" left="56" width="240" height="9" font="font4" id="p1_t28" reading_order_no="45" segment_no="8" tag_type="text">not detected in approximately one-quarter of cases in which</text>
<text top="543" left="56" width="241" height="9" font="font4" id="p1_t29" reading_order_no="46" segment_no="8" tag_type="text">the IHC assay for p53 was positive. We used stringent criteria</text>
<text top="555" left="56" width="240" height="9" font="font4" id="p1_t30" reading_order_no="47" segment_no="8" tag_type="text">for the classification of mutations; only those included in the</text>
<text top="567" left="56" width="240" height="9" font="font4" id="p1_t31" reading_order_no="48" segment_no="8" tag_type="text">p53 mutation database maintained at HÃ´pital Necker-Enfants</text>
<text top="579" left="56" width="240" height="9" font="font4" id="p1_t32" reading_order_no="49" segment_no="8" tag_type="text">Malades were considered true mutations. Furthermore, it is</text>
<text top="590" left="56" width="240" height="9" font="font4" id="p1_t33" reading_order_no="50" segment_no="8" tag_type="text">possible that some of the mutations identified by sequencing</text>
<text top="602" left="56" width="240" height="9" font="font4" id="p1_t34" reading_order_no="51" segment_no="8" tag_type="text">but not included in the database represent true functional</text>
<text top="614" left="56" width="40" height="9" font="font4" id="p1_t35" reading_order_no="52" segment_no="8" tag_type="text">mutations.</text>
<text top="637" left="56" width="241" height="9" font="font4" id="p1_t36" reading_order_no="53" segment_no="10" tag_type="text">Large, population-based studies have documented racial dis-</text>
<text top="649" left="56" width="240" height="9" font="font4" id="p1_t37" reading_order_no="54" segment_no="10" tag_type="text">parities in breast cancer outcomes [43]. As demonstrated by</text>
<text top="661" left="56" width="240" height="9" font="font4" id="p1_t38" reading_order_no="55" segment_no="10" tag_type="text">Polite and coworkers [44], self-reported African-American</text>
<text top="673" left="56" width="240" height="9" font="font4" id="p1_t39" reading_order_no="56" segment_no="10" tag_type="text">women from CALGB 9342 had decreased survival as com-</text>
<text top="684" left="56" width="240" height="9" font="font4" id="p1_t40" reading_order_no="57" segment_no="10" tag_type="text">pared with their Caucasian counterparts, even with adjust-</text>
<text top="696" left="56" width="241" height="9" font="font4" id="p1_t41" reading_order_no="58" segment_no="10" tag_type="text">ment for other factors. In this biomarker substudy, we<a href="">omes [43]. As de</a>monstrated by</text>
<text top="708" left="56" width="240" height="9" font="font4" id="p1_t42" reading_order_no="59" segment_no="10" tag_type="text">observed the association between African-American race and<a href="">workers [44],</a> self-reported African-American</text>
<text top="720" left="56" width="240" height="9" font="font4" id="p1_t43" reading_order_no="60" segment_no="10" tag_type="text">worse outcome. A potential explanation for these findings is</text>
<text top="226" left="315" width="240" height="9" font="font4" id="p1_t44" reading_order_no="61" segment_no="6" tag_type="text">the observation that these patients were twice as likely to have</text>
<text top="238" left="315" width="240" height="9" font="font4" id="p1_t45" reading_order_no="62" segment_no="6" tag_type="text">tumors that were negative for ER, PR and HER2, and triple-</text>
<text top="250" left="315" width="240" height="9" font="font4" id="p1_t46" reading_order_no="63" segment_no="6" tag_type="text">negative status was itself associated with significantly poorer</text>
<text top="261" left="315" width="240" height="9" font="font4" id="p1_t47" reading_order_no="64" segment_no="6" tag_type="text">OS. Because we did not collect data on post-study treatment,</text>
<text top="273" left="315" width="240" height="9" font="font4" id="p1_t48" reading_order_no="65" segment_no="6" tag_type="text">we cannot rule out differences in care received after the study</text>
<text top="285" left="315" width="240" height="9" font="font4" id="p1_t49" reading_order_no="66" segment_no="6" tag_type="text">as a cause of the observed disparity. However, our results</text>
<text top="297" left="315" width="240" height="9" font="font4" id="p1_t50" reading_order_no="67" segment_no="6" tag_type="text">extend the observations of Olopade [36] and Carey [35] and</text>
<text top="308" left="315" width="240" height="9" font="font4" id="p1_t51" reading_order_no="68" segment_no="6" tag_type="text">their groups, who reported that basal-like tumors are more</text>
<text top="320" left="315" width="240" height="9" font="font4" id="p1_t52" reading_order_no="69" segment_no="6" tag_type="text">common in women of African ancestry. Because the basal-like</text>
<text top="332" left="315" width="240" height="9" font="font4" id="p1_t53" reading_order_no="70" segment_no="6" tag_type="text">phenotype has been associated with a poor prognosis, our</text>
<text top="344" left="315" width="240" height="9" font="font4" id="p1_t54" reading_order_no="71" segment_no="6" tag_type="text">findings suggest that differences in the biologic features of<a href="">ns of Olopade [36] and Carey [35] and</a></text>
<text top="355" left="315" width="240" height="9" font="font4" id="p1_t55" reading_order_no="72" segment_no="6" tag_type="text">tumors may explain the decreased survival of African-American</text>
<text top="367" left="315" width="240" height="9" font="font4" id="p1_t56" reading_order_no="73" segment_no="6" tag_type="text">women in our study. To our knowledge, this is the first study to</text>
<text top="379" left="315" width="240" height="9" font="font4" id="p1_t57" reading_order_no="74" segment_no="6" tag_type="text">demonstrate that the association between a poor prognosis</text>
<text top="391" left="315" width="240" height="9" font="font4" id="p1_t58" reading_order_no="75" segment_no="6" tag_type="text">and the triple-negative phenotype persists in women with met-</text>
<text top="402" left="315" width="84" height="9" font="font4" id="p1_t59" reading_order_no="76" segment_no="6" tag_type="text">astatic breast cancer.</text>
<text top="426" left="315" width="240" height="9" font="font4" id="p1_t60" reading_order_no="77" segment_no="9" tag_type="text">The study had several limitations. First, we were able to obtain</text>
<text top="438" left="315" width="240" height="9" font="font4" id="p1_t61" reading_order_no="78" segment_no="9" tag_type="text">adequate tumor blocks from only approximately one-third of</text>
<text top="449" left="315" width="240" height="9" font="font4" id="p1_t62" reading_order_no="79" segment_no="9" tag_type="text">patients enrolled in CALGB 9342. As a result, the power to</text>
<text top="461" left="315" width="240" height="9" font="font4" id="p1_t63" reading_order_no="80" segment_no="9" tag_type="text">detect all but substantial differences in outcomes based on</text>
<text top="473" left="315" width="240" height="9" font="font4" id="p1_t64" reading_order_no="81" segment_no="9" tag_type="text">biomarkers was limited. Second, we cannot rule out the possi-</text>
<text top="485" left="315" width="240" height="9" font="font4" id="p1_t65" reading_order_no="82" segment_no="9" tag_type="text">bility that the dose-response curve for paclitaxel differs</text>
<text top="496" left="315" width="241" height="9" font="font4" id="p1_t66" reading_order_no="83" segment_no="9" tag_type="text">according to HER2 status; unfortunately, our sample was not</text>
<text top="508" left="315" width="240" height="9" font="font4" id="p1_t67" reading_order_no="84" segment_no="9" tag_type="text">large enough to carry out such an analysis. Third, 90% of the</text>
<text top="520" left="315" width="240" height="9" font="font4" id="p1_t68" reading_order_no="85" segment_no="9" tag_type="text">biomarker assays were performed on blocks from primary</text>
<text top="532" left="315" width="240" height="9" font="font4" id="p1_t69" reading_order_no="86" segment_no="9" tag_type="text">tumors (and 10% on blocks from synchronous lymph-node</text>
<text top="543" left="315" width="240" height="9" font="font4" id="p1_t70" reading_order_no="87" segment_no="9" tag_type="text">metastases), on the assumption that HER2 status is stable</text>
<text top="555" left="315" width="240" height="9" font="font4" id="p1_t71" reading_order_no="88" segment_no="9" tag_type="text">over time regardless of disease progression or interim thera-</text>
<text top="567" left="315" width="240" height="9" font="font4" id="p1_t72" reading_order_no="89" segment_no="9" tag_type="text">pies. A recent abstract has questioned this assumption [45],</text>
<text top="579" left="315" width="240" height="9" font="font4" id="p1_t73" reading_order_no="90" segment_no="9" tag_type="text">reporting discordance in HER2 expression between primary</text>
<text top="590" left="315" width="240" height="9" font="font4" id="p1_t74" reading_order_no="91" segment_no="9" tag_type="text">and metastatic sites in eight (14%) of 58 patients. Finally, pat-</text>
<text top="602" left="315" width="240" height="9" font="font4" id="p1_t75" reading_order_no="92" segment_no="9" tag_type="text">terns of gene expression may ultimately be more useful than</text>
<text top="614" left="315" width="240" height="9" font="font4" id="p1_t76" reading_order_no="93" segment_no="9" tag_type="text">single gene markers in predicting the response to therapy [46-<a href=""> [45]</a>,</text>
<text top="626" left="315" width="16" height="9" font="font4" id="p1_t77" reading_order_no="94" segment_no="9" tag_type="text">48].</text>
<text top="649" left="315" width="59" height="10" font="font6" id="p1_t78" reading_order_no="95" segment_no="11" tag_type="title">Conclusion</text>
<text top="661" left="315" width="240" height="9" font="font4" id="p1_t79" reading_order_no="96" segment_no="12" tag_type="text">Molecular subtyping has become commonplace in breast can-</text>
<text top="673" left="315" width="240" height="9" font="font4" id="p1_t80" reading_order_no="97" segment_no="12" tag_type="text">cer, but the implications of molecular markers in patients with<a href="">sponse to therapy [46-</a></text>
<text top="684" left="315" width="240" height="9" font="font4" id="p1_t81" reading_order_no="98" segment_no="12" tag_type="text">metastatic disease remains unclear. This study suggests that<a href="">48].</a></text>
<text top="696" left="315" width="240" height="9" font="font4" id="p1_t82" reading_order_no="99" segment_no="12" tag_type="text">tumor response is not dictated by p53, HER2 or ER status, but<b>Conclusion</b></text>
<text top="708" left="315" width="240" height="9" font="font4" id="p1_t83" reading_order_no="100" segment_no="12" tag_type="text">that these tumor features impact on tumor regrowth and death</text>
<text top="720" left="315" width="240" height="9" font="font4" id="p1_t84" reading_order_no="101" segment_no="12" tag_type="text">in patients with metastatic breast cancer. In addition, the</text>
<text top="85" left="56" width="28" height="7" font="font7" id="p1_t85" reading_order_no="1" segment_no="1" tag_type="title">Table 7</text>
<text top="104" left="56" width="114" height="7" font="font7" id="p1_t86" reading_order_no="2" segment_no="2" tag_type="text">Race according to biomarkers</text>
<text top="123" left="60" width="34" height="7" font="font1" id="p1_t87" reading_order_no="3" segment_no="3" tag_type="table">Biomarker</text>
<text top="123" left="297" width="18" height="7" font="font1" id="p1_t88" reading_order_no="4" segment_no="3" tag_type="table">Race</text>
<text top="122" left="434" width="28" height="8" font="font2" id="p1_t89" reading_order_no="5" segment_no="3" tag_type="table">P value a<b>Table 7</b></text>
<text top="140" left="185" width="36" height="7" font="font1" id="p1_t90" reading_order_no="6" segment_no="3" tag_type="table">Caucasian<b>Race according to biomarkers</b></text>
<text top="140" left="310" width="58" height="7" font="font1" id="p1_t91" reading_order_no="7" segment_no="3" tag_type="table">African-American</text>
<text top="159" left="60" width="38" height="7" font="font1" id="p1_t92" reading_order_no="8" segment_no="3" tag_type="table">ER positive</text>
<text top="159" left="185" width="50" height="7" font="font1" id="p1_t93" reading_order_no="9" segment_no="3" tag_type="table">58/109 (53%)<i>P </i></text>
<text top="159" left="310" width="45" height="7" font="font1" id="p1_t94" reading_order_no="10" segment_no="3" tag_type="table">13/32 (41%)</text>
<text top="159" left="435" width="16" height="7" font="font1" id="p1_t95" reading_order_no="11" segment_no="3" tag_type="table">0.21</text>
<text top="174" left="60" width="49" height="7" font="font1" id="p1_t96" reading_order_no="12" segment_no="3" tag_type="table">HER2 positive</text>
<text top="174" left="185" width="50" height="7" font="font1" id="p1_t97" reading_order_no="13" segment_no="3" tag_type="table">27/121 (22%)</text>
<text top="174" left="310" width="36" height="7" font="font1" id="p1_t98" reading_order_no="14" segment_no="3" tag_type="table">3/34 (9%)</text>
<text top="174" left="434" width="16" height="7" font="font1" id="p1_t99" reading_order_no="15" segment_no="3" tag_type="table">0.08</text>
<text top="190" left="60" width="50" height="7" font="font1" id="p1_t100" reading_order_no="16" segment_no="3" tag_type="table">Triple negative</text>
<text top="190" left="185" width="50" height="7" font="font1" id="p1_t101" reading_order_no="17" segment_no="3" tag_type="table">26/121 (21%)</text>
<text top="190" left="310" width="45" height="7" font="font1" id="p1_t102" reading_order_no="18" segment_no="3" tag_type="table">16/34 (47%)</text>
<text top="190" left="434" width="20" height="7" font="font1" id="p1_t103" reading_order_no="19" segment_no="3" tag_type="table">0.003</text>
<text top="206" left="60" width="255" height="7" font="font2" id="p1_t104" reading_order_no="20" segment_no="4" tag_type="text">a P values were obtained using a test of proportions. ER, estrogen receptor.</text>
</page>
</pdf2xml>
